We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Allen, R. C. & White, H. C. (1972) Side effects of long-acting phenothiazines.British Medical Journal, i, 807.Google Scholar
Caroff, S. N. (1980) The neuroleptic malignant syndrome.Journal of Clinical Psychiatry, 41, 79–83.Google Scholar
Cohen, W. J. & Cohen, N. H. (1974) Lithium carbonate, haloperidol and irreversible brain damage.Journal of the American Medical Association, 230, 1283–7.Google ScholarPubMed
Cope, R. V. & Gregg, E. M. (1983) The neuroleptic malignant syndrome.British Medical Journal, 286, 1938.Google Scholar
Delay, J., Pichot, P. & Lemperiere, T. (1960) Un neuroleptique majeur non phenothiazine et non reserpinique l'haloperidol dans le traitment des psychoses.Annates Medico-Psychologiques, 118, 145–52.Google Scholar
Itoh, M., Ohtsuka, N. & Ogita, K. (1977) Malignant Neuroleptic Syndrome: its present status in Japan and clinical problems.Folia Psychiatrica et Neurologica Japonica, 31, 565–76.Google ScholarPubMed
Meltzer, H. Y. (1973) Rigidity, hyperpyrexia and coma following fluphenazine enanthate.Psychopharmacologia, 29, 337–46.CrossRefGoogle ScholarPubMed
Smego, R. A. & Durack, D. T. (1982) The Neuroleptic Malignant Syndrome.Archives of Internal Medicine, 142, 1183–5.Google Scholar
Stauder, K. H. (1934). Die tödliche katatonia. Archiv für Psychiatrie und Nervenkrankheiten, 102, 614–34.Google Scholar
eLetters
No eLetters have been published for this article.